TAO Synergies Inc.

TAO Synergies Inc.

TAOX - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$12.93M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
TAO Synergies Inc.TAO Synergies Inc.-0.5--168062%--
$2.17

Current Fair Value

25.7% upside

Undervalued by 25.7% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$12.93 Million
Enterprise Value$10.56 Million
Earnings per Share$-8.81
Beta1.5
Outstanding Shares7,472,200

Return

Return on Equity-168062.02%ROE
Return on Assets-137723.51%
Return on Invested Capital-45070.90%

Valuation & Multiples

P/E Ratio-0.53P/E Ratio
PEG1.12PEG
Price to Sales-Price to Sales
Price to Book Ratio0.87Price to Book Ratio
Enterprise Value to Revenue124.71
Enterprise Value to EBIT0
Enterprise Value to Net Income-1
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 16, 2026
EPS
$0.38
Est. -$12.75
Revenue
$245,724
Est. $245,724

Next Earnings Call

Expected Date
March 3, 2027
EPS Estimate
-$12.75
Consensus analyst estimate
Revenue Estimate
$245,724
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %6.97%▼ 2.56%
Total Invested$2.36M▼ 11.13%
Investors Holding19▼ 9.00%

About Synaptogenix Inc

5 employees
CEO: Joshua N. Silverman

TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neuro...